Adding the IL-15 agonist to frontline BCG improved responses in carcinoma in situ without new safety signals; full data are expected at an upcoming congress.
|Videos|June 22, 2021
Pharmacist Medication Insights: Xembify for Primary Humoral Immunodeficiency Disease
Author(s)Saro Arakelians, PharmD
Xembify (immune globulin subcutaneous human–klhw) is a 20% immune globulin indicated for treatment of primary humoral immunodeficiency disease in patients 2 years of age and older.
Advertisement
Xembify (immune globulin subcutaneous human–klhw) is a 20% immune globulin indicated for treatment of primary humoral immunodeficiency disease in patients 2 years of age and older.
Xembify is contraindicated in patients who have had an anaphylactic or severe systemic reaction to the administration of human immune globulin. It is contraindicated in IgA-deficient patients with antibodies against IgA and a history of hypersensitivity.
Advertisement
Related to this article
The approval is supported by findings from the phase 3 OCEANIC-STROKE trial.
Every responsibility described in this issue depends on a pharmacy workforce with enough time and support to carry it.
As kratom questions increase, many pharmacists and other health care professionals may remain unfamiliar with it and with the potential risks.
Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.
Twice-daily metronidazole dosing had outcomes comparable with those of thrice-daily dosing for confirmed anaerobic infections, minimizing drug exposure and cost while maintaining clinical efficacy.
Two Kidney Week 2026 posters suggest remnant cholesterol–based markers may help stratify CKD severity and cardiovascular death risk on hemodialysis.
SCOUT-HCM data show LVOT gradient reductions persisted, patients switching from placebo responded similarly, and no patient had LVEF below 50%.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Asundexian Receives FDA Approval, Becomes First FXIa Inhibitor for Secondary Stroke Risk Reduction
2
FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk
3
mRNA vs Protein-Based COVID-19 Vaccines: What Pharmacists Can Tell Patients
4
Lilly–Hims & Hers GLP-1 Deal Tests Whether Convenience Can Deliver Continuity of Care
5